IRX-211
Magnitude of Opportunity
Pain Management Market
The pain management market is estimated to be worth $75 billion (USD) in 2023.
$75
Billion (USD)
IN 2023
- Inhaled analgesic therapies outside of a clinical setting are uncommon.
- Nasal formulations of fentanyl (e.g. Lazanda) have shown to be efficacious, however these were withdrawn due to safety concerns.
- Sublingual fentanyl products (e.g. Actiq, and Fentora) remain as the main treatment options for intense breakthrough pain. Abstral has also been withdrawn in the US.
IRX-211
Breakthrough Cancer Pain Solution
IRX-211 aims to revolutionise the management of Breakthrough Cancer Pain (BTcP) with a non-opioid, rapid-onset inhaled therapy.
Proven Safety
Phase I clinical trials for IRX-211 have been completed with no significant adverse events, showcasing strong safety data.
Regulatory Pathway Defined
The FDA has provided supportive feedback positioning IRX-211 for expedited regulatory approval and commercialisation.
Massive Market Potential
With a $9 billion addressable market in cancer pain by 2028, IRX-211 targets a significant unmet need in pain management.
Global Accessibility
FDA approval paves the way for subsequent approvals in Europe (EMA) and Australia (TGA), enabling broad patient access.
Scalable Demand
Addressing the needs of 1.8 million cancer patients in the U.S. alone, IRX-211 meets the growing demand for effective, non-opioid therapeutic options.
